繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Cipher Pharmaceuticals报告财年业绩

2026-03-13 05:13

  • Cipher Pharmaceuticals press release (CPHRF): FY Revenue of $50.5M.
  • Full year net income of $27.3 million, an increase of 137% over fiscal 2024
  • Full year adjusted EBITDA1 of $28.1 million, an increase of 79% over fiscal 2024
  • Generated $8.7 million in cash from operations during Q4 2025 and $29.7 million for the full year
  • Debt repayments of $35.0 million in fiscal 2025, with $7.5 million cash balance which exceeds outstanding long-term debt of $5.0 million at December 31, 2025
  • $5.4 million in share repurchases under Normal Course Issuer Bid during fiscal 2025

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。